The use of the peroxisome proliferator-activated receptors γ agonist rosiglitazone to treat airway hyperreactivity.
Manbir Singh
MS
Sandhu
Vesselin
V
Dimov
Arveen Kaur
AK
Sandhu
Ryan W
RW
Walters
Tammy
T
Wichman
Thomas
T
Casale
D000328:Adult; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D001944:Breath Tests; D016535:Bronchial Hyperreactivity / Q000188:drug therapy*; D015331:Cohort Studies; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D016210:Methacholine Chloride; D051379:Mice; D008875:Middle Aged; D009569:Nitric Oxide / Q000032:analysis; D047495:PPAR gamma / Q000819:agonists*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D016210:Methacholine Chloride; D009569:Nitric Oxide